CrystalGenomics gears up to begin Phase III of 'next-generation NSAID'
This article was originally published in Scrip
Executive Summary
CrystalGenomics has reported plans to begin a Phase III trial of its "next-generation NSAID candidate", CG100649, after a Phase IIb osteoarthritis (OA) study investigating the drug met its primary and secondary endpoints.